Azora Therapeutics, Inc. (AZR)
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Industry: Medical - Pharmaceuticals
Azora Therapeutics, Inc.
NASDAQ:AZRHealthcare · Biotechnology
PrePre-market+4.20%$3.97
Close$5.05+36.12%
Mkt Cap$13.26M
Float1.66M
O/S2.63M
Vol
$ Vol
RVOL
Inst Own-
SI10.8%
Earnings
Dilution
Pipeline1 lead-sponsored trial·0 active1 completed
Trials need funding. See this company's dilution risk and cash position.
Clinical Trials
- Phase 3Completed
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
AD04 (ondansetron), Matching placebo
Alcohol Use Disorder
NCT04101227Enrollment302StartFeb 2020Primary CompletionFeb 2022CompletionMar 2022
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 3 | Completed | AD04 (ondansetron), Matching placebo | NCT04101227 |